Volagidemab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | REMD-477; AMG-477 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Volagidemab (development name REMD-477) is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes. A phase II trial did not meet its primary endpoint.[1][2][3]
Research
[edit]A systematic review and meta-analysis of volagidemab, published in 2024, found it to be potentially beneficial in the treatment of type 1 diabetes.[4]
References
[edit]- ^ Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, et al. (May 2018). "Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial". Diabetes, Obesity and Metabolism. 20 (5): 1302–1305. doi:10.1111/dom.13202. PMC 6181222. PMID 29283470.
- ^ Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. (1 June 2021). "236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial". Diabetes. 70 (Supplement 1). doi:10.2337/db21-236-OR. S2CID 237783919.
- ^ Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. (October 2022). "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial". Nature Medicine. 28 (10): 2092–2099. doi:10.1038/s41591-022-02011-x. PMC 9872851. PMID 36192552.
- ^ Dutta D, Kamrul-Hasan AB, Surana V, Singla R, Khandelwal D, Aggarwal S, et al. (December 2024). "Efficacy and safety of the glucagon receptor antagonist volagidemab in type-1 diabetes: A systematic review and meta-analysis". Annals of the New York Academy of Sciences. doi:10.1111/nyas.15262. PMID 39625039.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |